Myomo, Inc. (NYSEAMERICAN:MYO – Free Report) – Equities researchers at HC Wainwright reduced their Q3 2026 earnings estimates for shares of Myomo in a research note issued on Friday, August 7th. HC Wainwright analyst S. Lee now expects that the company will post earnings of ($0.08) per share for the quarter, down from their previous estimate of ($0.07). The consensus estimate for Myomo’s current full-year earnings is ($0.29) per share. HC Wainwright also issued estimates for Myomo’s Q4 2026 earnings at ($0.07) EPS, FY2026 earnings at ($0.32) EPS, Q1 2027 earnings at ($0.08) EPS, Q2 2027 earnings at ($0.07) EPS, Q3 2027 earnings at ($0.07) EPS, Q4 2027 earnings at ($0.06) EPS, FY2027 earnings at ($0.28) EPS, FY2028 earnings at ($0.18) EPS, FY2029 earnings at $0.02 EPS and FY2030 earnings at $0.26 EPS.
Separately, Ascendiant Capital Markets boosted their target price on shares of Myomo from $9.50 to $10.00 and gave the stock a “buy” rating in a research note on Monday, June 8th. Three analysts have rated the stock with a Buy rating, According to data from MarketBeat, Myomo presently has a consensus rating of “Buy” and an average price target of $7.50.
Myomo Stock Performance
MYO opened at $1.43 on Tuesday. The firm has a fifty day moving average price of $1.15 and a 200 day moving average price of $0.93. The company has a debt-to-equity ratio of 1.98, a current ratio of 2.31 and a quick ratio of 2.01. Myomo has a 1 year low of $0.60 and a 1 year high of $1.84. The stock has a market cap of $56.64 million, a P/E ratio of -4.21 and a beta of 1.50.
Insider Buying and Selling
In other Myomo news, Director Thomas F. Kirk bought 43,401 shares of the business’s stock in a transaction dated Monday, May 18th. The shares were acquired at an average cost of $0.91 per share, with a total value of $39,494.91. Following the acquisition, the director directly owned 628,863 shares of the company’s stock, valued at $572,265.33. The trade was a 7.41% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Joseph M. Jr. Manko acquired 170,830 shares of Myomo stock in a transaction on Thursday, May 14th. The shares were bought at an average cost of $0.86 per share, with a total value of $146,913.80. Following the completion of the purchase, the director owned 2,279,408 shares in the company, valued at $1,960,290.88. The trade was a 8.10% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased a total of 341,205 shares of company stock worth $317,748 in the last 90 days. 12.14% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
A number of hedge funds have recently added to or reduced their stakes in the stock. XTX Topco Ltd purchased a new stake in Myomo in the 4th quarter valued at approximately $148,000. AQR Capital Management LLC raised its position in shares of Myomo by 47.8% in the 4th quarter. AQR Capital Management LLC now owns 434,376 shares of the company’s stock worth $395,000 after buying an additional 140,427 shares during the period. State Street Corp lifted its stake in shares of Myomo by 5.1% in the 4th quarter. State Street Corp now owns 399,853 shares of the company’s stock valued at $364,000 after purchasing an additional 19,563 shares in the last quarter. Wells Fargo & Company MN lifted its position in Myomo by 103.1% during the fourth quarter. Wells Fargo & Company MN now owns 38,707 shares of the company’s stock valued at $35,000 after buying an additional 19,646 shares in the last quarter. Finally, Jane Street Group LLC acquired a new position in shares of Myomo during the 4th quarter valued at $64,000. 44.99% of the stock is owned by hedge funds and other institutional investors.
Myomo News Roundup
Here are the key news stories impacting Myomo this week:
- Neutral Sentiment: HC Wainwright’s updated projections still anticipate a path to profitability, with estimated earnings of $0.02 per share in fiscal 2029 and $0.26 in fiscal 2030, although both figures were reduced from prior forecasts. Myomo analyst estimates
- Negative Sentiment: The analyst lowered its fiscal 2026 EPS forecast to a loss of $0.32 from a loss of $0.24. Quarterly estimates were also reduced to losses of $0.08 for the third quarter and $0.07 for the fourth quarter.
- Negative Sentiment: Forecasts for fiscal 2027 were cut to a loss of $0.28 per share from a loss of $0.15. HC Wainwright now expects losses in each quarter of 2027, including $0.08 in the first quarter and $0.07 in the second and third quarters.
- Negative Sentiment: The fourth-quarter 2027 estimate was reduced to a loss of $0.06 per share from expected earnings of $0.02, while the new fiscal 2028 forecast calls for a $0.18 loss.
- Negative Sentiment: Longer-term revisions were also sharply lower: fiscal 2029 EPS fell to $0.02 from $0.22, and fiscal 2030 EPS declined to $0.26 from $0.39. These cuts weaken the investment case for a company with a market capitalization of roughly $57 million and a currently negative price-to-earnings ratio.
Myomo Company Profile
Myomo, Inc (NYSE American: MYO) is a medical robotics company specializing in developing and commercializing powered orthotic devices designed to restore mobility and function for individuals with upper-limb weakness. The company’s flagship product, the MyoPro®, is an FDA-cleared, wearable robotic orthosis that leverages proprietary sensors and actuators to detect and amplify users’ own muscle signals, enabling patients with conditions such as stroke, spinal cord injury, muscular dystrophy and other neuromuscular disorders to perform daily activities with greater independence.
Myomo markets the MyoPro through a network of licensed orthotic and prosthetic professionals, clinics and hospitals across North America.
Read More
- Five stocks we like better than Myomo
- China’s Athleisure Boom Is Not Lifting Every Brand Equally
- SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
- 3 Dividend Champion Utilities for a Market That Can’t Sit Still
- These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
Receive News & Ratings for Myomo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myomo and related companies with MarketBeat.com's FREE daily email newsletter.
